Gmail

Fwd: Fw: T1D Fund update

1 message

Sent: Friday, 05 June 2026 19:21:38
Subject: T1D Fund update

Sending on behalf of Aaron Kowalski, Chief Executive Officer;

I am writing to share an important leadership update at the T1D Fund and to ensure you, as leaders of the Breakthrough T1D organization, are fully informed of these developments.

After dedicated service to the Fund, Elizabeth Mily is leaving to pursue new opportunities. We are deeply grateful for her many contributions and her leadership. Sylvia Tobé and Lucio Iannone remain as Managing Directors of the Fund, and Dan McNamara remains as Head of Strategy and Industry Engagement, ensuring continuity in the work you have helped make possible.

I want to assure you that the Fund's mission, investment strategy, portfolio management, governance structure, operating processes, and commitment to accelerating therapies and cures for type 1 diabetes (T1D) remain as strong as ever. The Fund team continues to execute actively against its strategy, support our portfolio companies, and deploy capital in support of transformative therapies and cures for T1D. The Fund remains a critical part of the Breakthrough T1D organization and a key resource in advancing breakthroughs through every stage of the therapy and cures pipeline.

Reflecting that continued momentum, the T1D Fund made a new $5 million investment this week to advance disease-modifying therapies for type 1 diabetes. This investment is consistent with our strategy of deploying capital in support of transformative therapies and cures and reflects the Fund team's continued active execution — supporting portfolio companies and identifying opportunities to accelerate breakthroughs at every stage of the pipeline.

We have also strengthened the T1D Fund Board with several new leaders. I am pleased to introduce Joe Lacher, who has been appointed Chair of the Board, joining as a new member alongside Grant Beard, John Cammett, and Mike Boyle. John Cammett will also join the T1D Fund Investment Committee. They join continuing Board members Karen Jordan and me. The T1D Fund website has been updated with the bios for these leaders: T1DFund.org

Together, our employee and volunteer team members are dedicated to ensuring that every part of Breakthrough T1D builds upon the key tenets identified at the Fund's inception: leveraging synergies across all of Breakthrough T1D—including the Research and Advocacy Teams—as a key investment competitive advantage, and maintaining sufficient investment operational nimbleness and expertise to succeed in the venture space.

This focus positions us to best deliver on our mission and to continue accelerating life-changing breakthroughs to people with T1D. The underlying strategy and operating model remain as strong and sound as they have been since inception, when the T1D Fund was founded as an integral component of Breakthrough T1D (then JDRF) and our pipeline strategy.

I also want to make you aware that the Juvenile Diabetes Cure Alliance (JDCA) published a report this afternoon titled "Power Grab at the T1D Fund?" Please know that this publication contains numerous inaccurate and false statements. We are requesting retraction and will be issuing a full response. In the meantime, please do not hesitate to reach out to myself, Pam Morrisroe (pmorrisroe@bt1d.org), or Kathleen Seitz (kseitz@bt1d.org) if you have questions.

Thank you for your continued confidence in Breakthrough T1D and the Fund. Your leadership is essential to everything we are working to achieve, and that partnership matters now more than ever. Please don't hesitate to reach out if you have any questions—we would welcome the chance to talk further.

With gratitude,

Aaron J. Kowalski, Ph.D.

Breakthrough T1D Chief Executive Officer

T1D Fund Board Member

Breakthrough T1D™
Formerly JDRF

Aaron Kowalski
Chief ExecutiveOfficer
200 Vesey Street, 28th Floor
New York, NY 10281
o: 212-479-7512
akowalski@BreakthroughT1D.org
BreakthroughT1D.org